BioAge Labs (BIOA) risk factors, FY2024 10-K

Other

1. 01We have a limited operating history, have not completed any clinical trials beyond Phase 1b and have no products approved for commercial sale, which may make it difficult for investors to evaluate our business, likelihood of success and viability
2. 02If we are unable to advance the development of, receive regulatory approval for and ultimately successfully commercialize BGE-102 or any future product candidates we may develop, or experience significant delays in doing so, our business will be materially harmed
3. 03Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
4. 04We are subject to securities litigation , which is expensive and could divert management attention

Risks Related to Our Financial Position, Limited Operating History and Need for Additional Capital

1. 05We have a limited operating history, have not completed any clinical trials beyond Phase 1b and have no products approved for commercial sale, which may make it difficult for investors to evaluate our business, likelihood of success and viability
2. 06the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims

Risk Related to Research, Discovery, Development, Regulatory Approval and Commercialization of our

1. 07maintaining a continued acceptable safety profile of the products following approval
2. 08the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial
3. 09experience damage to our reputation
4. 10We may develop future product candidates in combination with other therapies, which would expose us to additional risks
5. 11Preliminary, topline or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and/or are subject to audit and verification procedures that could result in material changes in the final data
6. 12We may not be successful in applying our longitudinal human aging platform to identify additional targets with therapeutic and commercial potential or in the discovery and development of commercially viable product candidates for us or our collaborators
7. 13Our future growth may be dependent, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
8. 14We may experience difficulty enrolling or keeping patients in our clinical trials, which could delay or prevent us from proceeding with, or otherwise adversely affect, clinical trials of our product candidates
9. 15Our current or future product candidates may not achieve adequate market acceptance among physicians, patients or their families, healthcare payors and others in the medical community necessary for commercial success
10. 16If any of our current or future product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results would be negatively impacted
11. 17unforeseen costs and expenses associated with creating an independent commercialization organization

Risks Related to Our Business and Operations

1. 18Our future performance is dependent on our ability to retain key employees and to attract, retain and motivate qualified personnel and manage our human capital
2. 19changes in general market and economic conditions
3. 20We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, if at all
4. 21The estimates of market opportunity and forecasts of market growth included in this Annual Report may prove to be smaller than we believe, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
5. 22Negative results or publicity for one obesity drug could have a substantial impact on all drugs and product candidates for the treatment of obesity, including any potential product candidates we may have in the future
6. 23We may engage in strategic transactions that could increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, subject us to other risks, adversely affect our liquidity, increase our expenses and present significant distractions to our management
7. 24Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
8. 25Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flows, financial condition or results of operations
9. 26Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
10. 27We and the third parties with whom we work are, or may in the future be, subject to stringent and changing data privacy and security obligations
11. 28We are dependent on the efficient and uninterrupted operation of our information technology systems, and those systems, or those of our third-party service providers, may be impacted by security incidents, cyberattacks, loss of data and other disruptions, which could adversely impact our business
12. 29Further, remote work may increase the risks to our information technology systems and data, as remotely working employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit or in public locations
13. 30We are an “emerging growth company” and a “smaller reporting company” and the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies could make our common stock less attractive to investors

Risks Related to Our Reliance on Third Parties

1. 31if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or, if approved, commercialization program could be delayed, diminished or terminated
2. 32failure to deliver our drugs under specified storage conditions and in a timely manner
3. 33If we, or any contract manufacturers or suppliers we engage, fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business

Risks Related to Intellectual Property

1. 34If we do not obtain patent term extension for any product candidates we may develop, our business may be harmed
2. 35Patent terms may be insufficient to protect our competitive position on BGE-102 and any future product candidates for an adequate amount of time
3. 36Obtaining and maintaining our patent protection is dependent on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 37patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects
5. 38If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected
6. 39Intellectual property rights do not necessarily address all potential threats to our business
7. 40Our rights to develop and commercialize any future products as well as our lead product candidate, BGE-102, are or may be subject to the terms and conditions of license agreements
8. 41If we breach our license agreements it could have a material adverse effect on our commercialization efforts for BGE-102 or any future product candidates
9. 42whether and the extent to which inventors are able to contest the assignment of their rights to our licensors
10. 43Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
11. 44redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time
12. 45We may not be able to protect our intellectual property rights throughout the world
13. 46If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 47Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators could be expensive and time consuming and may prevent or delay the development and commercialization of our product candidates
15. 48We may be subject to claims challenging the inventorship of our patents and other intellectual property
16. 49Third party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of our current or future product candidates or technologies

Risks Related to Government Regulation

1. 50Existing, recently enacted and future legislation may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and decrease the prices we may obtain
2. 51The insurance coverage and reimbursement status of newly approved products are uncertain. Failure to obtain or maintain coverage and adequate reimbursement for any future products could limit our ability to market those products and decrease our ability to generate revenue
3. 52Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
4. 53The acceptance by the FDA or other regulatory authorities of trial data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all
5. 54interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism

Risks Related to Our Common Stock

1. 55Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
2. 56In addition, Section 203 of the Delaware General Corporation Law (DGCL), may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock
3. 57The market price of our common stock is likely to be highly volatile, and you could lose all or part of your investment
4. 58general economic, industry and market conditions, including fluctuating interest rates and inflation
5. 59We do not currently intend to pay dividends on our common stock and, consequently, our stockholders’ ability to achieve a return on their investment will be dependent on appreciation of the value of our common stock
6. 60If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
7. 61Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell in the public market the market price of our stock could decline significantly
8. 62We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
9. 63We are subject to securities litigation, which is expensive and could divert management attention